Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Longo, D.
Right arrow Articles by DeVita, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Longo, D.
Right arrow Articles by DeVita, V., Jr

Journal of Clinical Oncology, Vol 10, 210-218, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

DL Longo, PL Duffey, RC Young, SM Hubbard, DC Ihde, E Glatstein, JC Phares, ES Jaffe, WJ Urba and VT DeVita Jr
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD.

PURPOSE: The study was undertaken to evaluate clinical prognostic factors, probability of response to therapy, duration of response, and overall survival of patients with Hodgkin's disease relapsing from a chemotherapy-induced complete remission. PATIENTS AND METHODS: Study population comprised 107 patients with Hodgkin's disease treated with combination chemotherapy at the National Cancer Institute who relapsed after achieving a complete remission. RESULTS: Half of the relapses occurred within the first year of achieving complete remission; among patients in remission 5 years or longer, only 4% relapsed. The overall survival of the relapsed patients is projected to be 17% at 20 years, calculated from the date of relapse. Primary treatment regimen, presence of B symptoms, stage, sex, liver involvement, pleural involvement, marrow involvement, and histologic subtype did not affect the survival of relapsed patients. Only age at diagnosis (older or younger than 30 years) and length of initial remission (shorter or longer than 1 year) made a significant impact on survival. Patients whose initial remission was longer than 1 year had significantly higher complete response rates to salvage therapy, significantly more durable second remissions, and significantly longer survival than patients whose initial remission was shorter than 1 year. Survival beyond 11 years from relapse of patients with long initial remissions was 24%; for those with short initial remissions, 11% (P2 = .027). Despite the fact that with salvage therapy, patients with long initial remission had an 85% complete response rate to mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) with a disease-free survival of 45% at 20 years, acute leukemia and other treatment-related complications combined to lower the survival rate of this more favorable subset. CONCLUSIONS: These data with conventional-dose salvage therapy provide results for comparison with novel salvage approaches including myeloablative therapy with autologous marrow or peripheral-blood stem- cell support.


This article has been cited by other articles:


Home page
 JCOHome page
Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices
J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Montalban, J. F. Garcia, V. Abraira, L. Gonzalez-Camacho, M. M. Morente, J. L. Bello, E. Conde, M. A. Cruz, R. Garcia-Sanz, J. Garcia-Larana, et al.
Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group
J. Clin. Oncol., May 1, 2004; 22(9): 1664 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Laskar, T. Gupta, S. Vimal, M.A. Muckaden, T.K. Saikia, S.K. Pai, K.N. Naresh, and K.A. Dinshaw
Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?
J. Clin. Oncol., January 1, 2004; 22(1): 62 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Constans, A. Sureda, M. J. Terol, R. Arranz, M. D. Caballero, A. Iriondo, I. Jarque, E. Carreras, J. M. Moraleda, D. Carrera, et al.
Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome
Ann. Onc., May 1, 2003; 14(5): 745 - 751.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al.
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Blood, March 1, 2003; 101(5): 2015 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Ferme, N. Mounier, M. Divine, P. Brice, A. Stamatoullas, O. Reman, L. Voillat, J. Jaubert, P. Lederlin, P. Colin, et al.
Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
J. Clin. Oncol., January 15, 2002; 20(2): 467 - 475.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Josting, J. Franklin, M. May, P. Koch, M. K. Beykirch, J. Heinz, C. Rudolph, V. Diehl, and A. Engert
New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study Group
J. Clin. Oncol., January 1, 2002; 20(1): 221 - 230.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. A. Mink and J. O. Armitage
High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma
Oncologist, June 1, 2001; 6(3): 247 - 256.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. G. Gobbi, M. L. Ghirardelli, M. Solcia, G. Di Giulio, F. Merli, L. Tavecchia, R. Berte, O. Davini, A. Levis, C. Broglia, et al.
Image-Aided Estimate of Tumor Burden in Hodgkin's Disease: Evidence of Its Primary Prognostic Importance
J. Clin. Oncol., March 1, 2001; 19(5): 1388 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J.J. Lahuerta, J. Garcia-Conde, I. Jarque, M.D. Caballero, C. Ferra, A. Lopez, et al.
Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
J. Clin. Oncol., March 1, 2001; 19(5): 1395 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. H. Moskowitz, S. D. Nimer, A. D. Zelenetz, T. Trippett, E. E. Hedrick, D. A. Filippa, D. Louie, M. Gonzales, J. Walits, N. Coady-Lyons, et al.
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
Blood, February 1, 2001; 97(3): 616 - 623.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Josting, U. Rueffer, J. Franklin, M. Sieber, V. Diehl, and A. Engert
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group
Blood, August 15, 2000; 96(4): 1280 - 1286.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. D. Baynes, C. Hamm, R. Dansey, J. Klein, L. Cassells, C. Karanes, E. Abella, and W. P. Peters
Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting
Clin. Chem., August 1, 2000; 46(8): 1239 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Santoro, H. Bredenfeld, L. Devizzi, H. Tesch, V. Bonfante, S. Viviani, F. Fiedler, H. S. Parra, C. Benoehr, M. Pacini, et al.
Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study
J. Clin. Oncol., July 1, 2000; 18(13): 2615 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Ferme, C. Sebban, C. Hennequin, M. Divine, P. Lederlin, J. Gabarre, A. Ferrant, D. Caillot, D. Bordessoule, P. Brice, et al.
Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial
Blood, April 1, 2000; 95(7): 2246 - 2252.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Josting, M. Reiser, U. Rueffer, B. Salzberger, V. Diehl, and A. Engert
Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?
J. Clin. Oncol., January 14, 2000; 18(2): 332 - 332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Sweetenham, A. M. Carella, G. Taghipour, D. Cunningham, R. Marcus, A. D. Volpe, D. C. Linch, N. Schmitz, and A. H. Goldstone
High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation
J. Clin. Oncol., October 1, 1999; 17(10): 3101 - 3109.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. G. Murray, L. J. Billingham, H. T. Hassan, J. R. Flavell, P. N. Nelson, K. Scott, G. Reynolds, C. M. Constandinou, D. J. Kerr, E. C. Devey, et al.
Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkin's Disease
Blood, July 15, 1999; 94(2): 442 - 447.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Rodriguez, M.A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A. Sarris, J. Romaguera, B. Andersson, F. Cabanillas, and F.B. Hagemeister
ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease
Blood, June 1, 1999; 93(11): 3632 - 3636.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. H. M. Lazarus, P. A. Rowlings, M.-J. Zhang, J. M. Vose, J. O. Armitage, P. J. Bierman, J. L. Gajewski, R. P. Gale, A. Keating, J. P. Klein, et al.
Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry
J. Clin. Oncol., February 1, 1999; 17(2): 534 - 534.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Andre, M. Henry-Amar, J.-L. Pico, P. Brice, D. Blaise, M. Kuentz, B. Coiffier, P. Colombat, J.-Y. Cahn, M. Attal, et al.
Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study
J. Clin. Oncol., January 1, 1999; 17(1): 222 - 222.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Hasenclever, V. Diehl, J. O. Armitage, D. Assouline, M. Bjorkholm, E. Brusamolino, G. P. Canellos, P. Carde, D. Crowther, D. Cunningham, et al.
A Prognostic Score for Advanced Hodgkin's Disease
N. Engl. J. Med., November 19, 1998; 339(21): 1506 - 1514.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, M. Henry-Amar, D. Blaise, P. Colombat, J. Fleury, N. Milpied, J.-Y. Cahn, J.-L. Pico, Y. Bastion, M. Kuentz, et al.
Treatment-Related Deaths and Second Cancer Risk After Autologous Stem-Cell Transplantation for Hodgkin's Disease
Blood, September 15, 1998; 92(6): 1933 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. P. Sing, R. F. Ambinder, D. J. Hong, M. Jensen, W. Batten, E. Petersdorf, and P. D. Greenberg
Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes That Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV+ Hodgkin's Disease
Blood, March 15, 1997; 89(6): 1978 - 1986.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Horning, N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume
High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis of the Stanford University Results and Prognostic Indices
Blood, February 1, 1997; 89(3): 801 - 813.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. S. Multani and M. L. Grossbard
Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?
Oncologist, February 1, 1996; 1(1): 41 - 55.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
V. T. DeVita and S. M. Hubbard
Hodgkin's Disease
N. Engl. J. Med., February 25, 1993; 328(8): 560 - 565.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1992 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online